Benefit-Risk Assessment of Irinotecan in Advanced Colorectal Cancer

ISSN： 0114-5916

Source： Drug Safety, Vol.28, Iss.5, 2005-01, pp. : 417-433

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer

By Dienstmann Rodrigo

Drug Safety, Vol. 35, Iss. 1, 2012-01 ,pp. : 15-25

Adis International

Access to resources Recommend Favorite

Benefit-Risk Assessment of Sunitinib in Gastrointestinal Stromal Tumours and Renal Cancer

By Theou-Anton Nathalie Faivre Sandrine Dreyer Chantal Raymond Eric

Drug Safety, Vol. 32, Iss. 9, 2009-09 ,pp. : 717-734

Adis International

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Irinotecan in Solid Tumours

By Siu L.L. Rowinsky E.K.

Drug Safety, Vol. 18, Iss. 6, 1998-06 ,pp. : 395-417

Adis International

Access to resources Recommend Favorite

Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer

By Cao Shousong Bhattacharya Arup Durrani Farukh A Fakih Marwan

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 6, 2006-04 ,pp. : 687-703

Informa Healthcare

Access to resources Recommend Favorite

A Benefit-Risk Assessment of Erlotinib in Non-Small-Cell Lung Cancer and Pancreatic Cancer

By Mountzios Giannis

Drug Safety, Vol. 34, Iss. 3, 2011-03 ,pp. : 175-186

Adis International

Access to resources Recommend Favorite